American Thoracic Society - Sanofi Investor Call

Dupilumab Mechanism of Action Viruses Bacteria Smoke/pollutants Airway epithelium Type 2 inflammatory cytokines IL-5 IL-4 IL-13 Goblet cell hyperplasia Dupilumab blocks the shared receptor component for IL-4 and IL-13 Eosinophil activation TH2 cell differentiation Mast cell degranulation Type 2 inflammation (20 to 40% of COPD) Airflow obstruction ATS 2023 Exacerbation Lung function decline Airway remodeling & lung parenchyma destruction Le Floc'h A, et al. Allergy. 2020 19

View entire presentation